John Libbey Eurotext

European Journal of Dermatology

MENU

Safety and efficacy of secukinumab in psoriasis patients infected with hepatitis B virus: a retrospective study Volume 32, numéro 3, May-June 2022

  • [1.] Gudjonsson JE, Elder JT. Psoriasis: epidemiology. Clin Dermatol 2007; 25: 535-46.
  • [2.] Blauvelt A. Safety of secukinumab in the treatment of psoriasis. Expert Opin Drug Saf 2016; 15: 1413-20.
  • [3.] Lonnberg AS, Zachariae C, Skov L. Targeting of interleukin-17 in the treatment of psoriasis. Clin Cosmet Investig Dermatol 2014; 7: 251-9.
  • [4.] Sanford M, McKeage K. Secukinumab: first global approval. Drugs 2015; 75: 329-38.
  • [5.] Gaffen SL, Jain R, Garg AV, Cua DJ. The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol 2014; 14: 585-600.
  • [6.] Bao S, Zheng J, Shi G. The role of T helper 17 cells in the pathogenesis of hepatitis B virus-related liver cirrhosis (Review). Mol Med Rep 2017; 16: 3713-9.
  • [7.] Trepo C, Chan HL, Lok A. Hepatitis B virus infection. Lancet 2014; 384: 2053-63.
  • [8.] Cannizzaro MV, Franceschini C, Esposito M, Bianchi L, Giunta A. Hepatitis B reactivation in psoriasis patients treated with anti-TNF agents: prevention and management. Psoriasis 2017; 7: 35-40.
  • [9.] Wang H, Men P, Xiao Y, et al. Hepatitis B infection in the general population of China: a systematic review and meta-analysis. BMC Infect Dis 2019; 19: 811.
  • [10.] Manalo IF, Gilbert KE, Wu JJ. Preventing hepatitis B reactivation associated with immunosuppressive drug treatments for psoriasis. J Am Acad Dermatol 2015; 73: 881-2.
  • [11.] Snast I, Atzmony L, Braun M, Hodak E, Pavlovsky L. Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: a retrospective cohort study and systematic review of the literature. J Am Acad Dermatol 2017; 77: 88-97.e85.
  • [12.] Hoofnagle JH. Reactivation of hepatitis B. Hepatology 2009; 49: S156-165.
  • [13.] Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis – results of two phase 3 trials. N Engl J Med 2014; 371: 326-38.
  • [14.] Thaci D, Blauvelt A, Reich K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol 2015; 73: 400-9.
  • [15.] Raimondo A, Balato A, Megna M, Balato N. Limitations of current monoclonal antibodies for plaque-type psoriasis and an outlook for the future. Expert Opin Biol Ther 2018; 18: 605-7.
  • [16.] Gisondi P, Altomare G, Ayala F, et al. Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol 2017; 31: 774-90.
  • [17.] Kaushik SB, Lebwohl MG. Psoriasis: Which therapy for which patient: Psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol 2019; 80: 27-40.
  • [18.] Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: focus on special populations and chronic infections. J Am Acad Dermatol 2019; 80: 43-53.
  • [19.] van Denderen JC, Blom GJ, van der Horst-Bruinsma IE, Dijkmans BA, Nurmohamed MT. Elevated liver enzymes in patients with ankylosing spondylitis treated with etanercept. Clin Rheumatol 2012; 31: 1677-82.
  • [20.] Beringer A, Miossec P. IL-17 and IL-17-producing cells and liver diseases, with focus on autoimmune liver diseases. Autoimmun Rev 2018; 17: 1176-85.
  • [21.] Chiu HY, Hui RC, Huang YH, et al. Safety profile of secukinumab in treatment of patients with psoriasis and concurrent hepatitis B or C: a multicentric prospective cohort study. Acta Derm Venereol 2018; 98: 829-34.
  • [22.] Yanagihara S, Sugita K, Yoshida Y, Tsuruta D, Yamamoto O. Psoriasis vulgaris in a hepatitis B virus carrier successfully treated with secukinumab and entecavir combination therapy. Eur J Dermatol 2017; 27: 185-6.